medigraphic.com
Órgano Oficial del Instituto Nacional de Pediatría

2020, Number S1

<< Back Next >>

Acta Pediatr Mex 2020; 41 (S1)

Immunopathology of SARS-CoV-2 virus infection

Espinosa-Rosales FJ

Language: Spanish
References: 10
Page: 42-50
PDF size: 875.49 Kb.


ABSTRACT

AFTER SARS-CoV-2 virus pandemic that started in 2019, it has been observed that the vast majority of people have a mild clinical picture or are completely asymptomatic. However, around 15% of affected people will have a severe, potentially fatal clinical course associated with hyperinflammation, similar to the macrophage activation syndromes. Individuals with mild clinical COVID-19 have an efficient innate immune response and an adaptive response that kills virus-infected cells leaving immune memory. Severe symptoms occur in individuals with proinflammatory stages who have a late innate immune response, hyperinflammation and “cytokine storm” phenomenon induced by the innate immune system and associated with defects in adaptive immunity.


REFERENCES

  1. Matricardi PM, et al. The first, holistic immunological model of COVID-19: implications for prevention, diagnosis, and public health measures. Pediatr Allergy Immunol. Accepted Author Manuscript. doi:10.1111/pai.13271

  2. Leo O, et al. Vaccine Immunology. Perspectives in Vaccinology 2011; 1: 25-59.

  3. Vabret N, et al. The Sinai Immunology Review Project, Immunology of COVID-19: current state of the science. Immunity (2020) https://doi.org/10.1016/ j.immuni.2020.05.002.

  4. Hallstrand TS, et al. Airway epithelial regulation of pulmonary immune homeostasis and inflammation. Clin Immunol. 2014; 151: 1-15. doi: 10.1016/j.clim.2013.12.003.

  5. Santosha A, et al. The many faces of the anti-COVID immune response. J Exp Med. 2020; 217 (6): e20200678. https://doi. org/10.1084/jem.20200678

  6. Richardson S, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area. JAMA. April 22, 2020. doi:10.1001/jama.2020.6775

  7. Pawelec G. Aging as an inflammatory disease and possible reversal strategies. J Allergy Clin Immunol. 2020; 145 (5): 1355-56. doi: 10.1016/j.jaci.2020.02.022.

  8. Chait A, den Hartigh LJ. Adipose tissue distribution, inflammation and its metabolic consequences, including diabetes and cardiovascular disease. Front Cardiovasc Med. 2020; 7: 22. doi: 10.3389/fcvm.2020.00022. eCollection 2020.

  9. Merad M, et al. Pathological inflammation in patients with COVID- 19: a key role for monocytes and macrophages. Nat Rev Immunol 2020. https://doi.org/10.1038/s41577-020-0331-4

  10. Wang F, et al. Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia. J Infect Dis 2020; 221: 1762-69. https://doi.org/10.1093/infdis/jiaa150




2020     |     www.medigraphic.com